On August 18, 2026, a clinical trial update was recorded for [212Pb]VMT-Alpha-NET, an agent targeting somatostatin-receptor positive tumors. The trial, registered as NCT06479811, is titled "[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers."
The study is listed as Phase 1 and its current status is recruiting. It is designed to evaluate the investigational agent in patients with somatostatin-receptor positive cancers, including gastrointestinal neuroendocrine tumors, pheochromocytoma and paraganglioma, small cell lung cancer, renal cell cancer, and head and neck cancers. Somatostatin itself remains classified as an unapproved research compound, and this trial concerns an investigational radiolabeled agent, [212Pb]VMT-Alpha-NET, developed to interact with somatostatin receptors.
No results, efficacy data, or safety outcomes have been reported as part of this update. The listing reflects only the trial's registration status, phase designation, and recruitment stage as of the update date. Further details on eligibility, design, and outcomes can be found through the official clinical trial registry entry.
Readers seeking general background on somatostatin can consult the compound overview for additional context.